Antibody‐based immunotherapies have dominated clinical trials for tauopathies, but since tau is an endogenous protein, these approaches pose a significant risk of adverse and potentially irreversible autoimmune responses.[5] Therefore, understanding the mechanisms driving tau hyperphosphorylation is crucial for developing precise therapeutic interventions, as a more refined approach beyond monoclonal antibodies may be required to effectively target tauopathies. This evidence concerns the gene MAPT and tauopathy.